What does anti-cd39 — development milestone expense mean?

This metric captures expenses incurred when specific development-related milestones are reached for anti-CD39 programs, often paid to research partners or licensors. It serves as a proxy for the successful execution of R&D phases and the fulfillment of external collaboration obligations. Monitoring this helps assess the financial impact of achieving key technical or clinical development goals.

Arcus Biosciences RCUS anti-CD39 — Development milestone expense

Similar metrics at other companies

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

IRONDISC Three Four Zero Five — Research And Development Expense

$9.19M+451%

IRONDISC Zero Nine Seven Four — Research And Development Expense

$8.11M+32.5%

DYNDYNE-251DM1 — Research And Development Expense

$37.75M+79.0%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.62B+226%

Enterprise value$3.53B+275%

P/S15.4×+7.5×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept rcus:MilestoneExpense.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's anti-cd39 — development milestone expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's anti-cd39 — development milestone expense?: Arcus Biosciences (RCUS) reported anti-cd39 — development milestone expense of $0 in Q1 2026.
What does anti-cd39 — development milestone expense mean?: This metric captures expenses incurred when specific development-related milestones are reached for anti-CD39 programs, often paid to research partners or licensors. It serves as a proxy for the successful execution of R&D phases and the fulfillment of external collaboration obligations. Monitoring this helps assess the financial impact of achieving key technical or clinical development goals.